A series of cardiometabolic-related news items has been observed from Altimmune, AstraZeneca, Insilico Medicine, and Lilly. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, AstraZeneca, Boehringer Ingelheim, and Abbott/Google. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from MHRA/Lilly, Veru, Ascletis Pharma, Novo Nordisk, and Neurocrine Biosciences. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Structure Therapeutics, Senseonics, Tandem Diabetes Care, and Biocon. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Insulet, NewAmsterdam Pharma, Protagonist Therapeutics, Biomea Fusion, Vivani Medical, and CVS Health. Below, FENIX provides highlights and insights for the respective news items.
Lilly hosted its Q2 ’26 earnings call and provided updates across its diabetes and obesity businesses (view press release; view slides). Of note, the company’s stock is up ~5% today after raising its FY 2026 sales guidance (now $85-87B vs. $82-85B) due to continued Mounjaro and Zepbound demand. Below, FENIX provides highlights and insights from the earnings call.
Novo Nordisk hosted its Q2 ’26 earnings call and provided updates across its diabetes and obesity businesses (view press release; view slides). Following the increase in FY 2026 adjusted sales guidance (now 0% to -6% vs. -4% to -12%) due to increased demand across its GLP-1RA franchise, the company’s stock is up ~1.3%. The drop in stock yesterday, after releasing its Q2 ’26 business updates (previous FENIX insight), was due to US Wegovy pill sales narrowly missing analyst consensus (view article), in addition to cagrisema failing to achieve non-inferior A1C reductions vs. tirzepatide in the Ph3 REIMAGINE 4 H2H study. Separately, Novo announced it won a preliminary injunction against Ceban Ziekenhuisfarmacie B.V., ordering the company to immediately stop selling a compounded semaglutide nasal spray infringing on Novo’s IP (view press release).
A series of cardiometabolic-related news items has been observed from AZ/BMS, Novo Nordisk, Merck, Pfizer, Amgen, Arrowhead Pharmaceuticals, Ascletis Pharma, Lilly, and Corbus Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items, including insights into how the rumored AZ/BMS merger may impact the future CVRM market.
Three cardiometabolic-related news items have been observed: Altimmune initiated the pivotal Ph3 PERFORMA trial in F2-F3 MASH (view press release); Amylyx Pharmaceuticals launched a post-bariatric hypoglycemia education website (view article); and Vertex Pharmaceuticals hosted its Q2 ’26 earnings call, disclosing a new T1DM cell therapy program (view press release; slides).
Three cardiometabolic-related news items have been observed: Dexcom hosted its Q2 ’26 earnings call (view press release; view slides); Novo’s Ph3 ZEUS trial evaluating ziltivekimab missed the primary CV endpoint (view press release); and CSPC initiated a Ph1 study evaluating its QM GLP-1/GIP dual agonist (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.